Owlet demonstrates a strong and evolving business model with defensible regulatory clearances and growing subscription revenue, which underpin sustainable growth and margin expansion. The company’s move into healthcare channel partnerships and international markets enhances optionality and reduces …
Owlet (OWLT) Q1 2025: 43% Revenue Surge Highlights Transition to Pediatric Health Platform
Owlet delivered a robust start to 2025 with strong revenue growth and margin expansion driven by its core infant monitoring products and accelerating subscription service adoption. The company’s strategic shift from hardware to a pediatric health platform is gaining traction, supported by new hospital partnerships and international expansion. Despite tariff headwinds, Owlet raised its revenue guidance, signaling confidence in sustainable growth and profitability improvements.
Summary
- Platform Evolution Momentum: Owlet is successfully transitioning from a hardware-focused business to a comprehensive pediatric health platform.
- Healthcare Channel Breakthrough: The first hospital consignment partnership enables infants to leave with Owlet monitors, opening new reimbursement pathways.
- Tariff Navigation and Market Share Opportunity: Strategic supply chain shifts mitigate tariff risks and position Owlet to gain share amid competitor exposure to China tariffs.
Business Overview
Owlet, Inc. is a healthcare growth company that develops FDA- and CE-cleared infant monitoring devices, including the Dream Sock and Dream Duo products, which provide real-time health data to parents. The company generates revenue primarily through device sales and its growing Owlet360 subscription service, which offers enhanced pediatric health insights. Owlet operates major segments including consumer hardware, subscription services, international sales, and healthcare channel partnerships.
Performance Analysis
Owlet reported first quarter 2025 revenue of $21.1 million, a 43.1% increase year-over-year, driven primarily by strong sales of its Dream Sock and Dream Duo infant health monitors. This growth outpaced expectations and was supported by a severe cold and flu season, which heightened demand for infant health monitoring. Gross margin expanded significantly by 930 basis points to 53.7%, marking the eighth consecutive quarter of margin improvement. This margin expansion reflects favorable product mix, notably toward higher-margin Dream Sock units, improved fixed cost absorption, and reduced return rates.
Operating expenses increased modestly to $14 million, driven by higher compensation and one-time litigation costs. Despite this, operating loss narrowed substantially to $2.7 million from $5.7 million a year earlier. Adjusted EBITDA reached break-even, improving $3.1 million from the prior year and marking the fourth consecutive quarter of adjusted EBITDA profitability or better. The company’s net income was $3 million, including a $6.7 million gain on warrant mark-to-market adjustments, underscoring improved financial discipline and operational leverage.
- Revenue Concentration: Core hardware products remain the primary revenue drivers, with international sales doubling and subscription revenue gaining traction.
- Margin Levers: Product mix shift toward Dream Sock and lower returns contributed materially to gross margin expansion.
- Operating Efficiency: Despite increased operating expenses, improved top-line and cost control enabled adjusted EBITDA break-even.
Overall, Owlet’s financial results demonstrate effective execution on growth and margin expansion, positioning the company for sustained profitability as it scales its platform offerings.
Executive Commentary
"We exceeded our expectations for first quarter 2025 results by executing on our growth strategies and leveraging our position as the only FDA and CE cleared infant health monitors on the market. As a result, we continue to capture market share as parents increasingly choose Owlet to improve overall infant health, sleep, and safety, driving 43% year-over-year growth and our fourth consecutive quarter of break-even or better adjusted EBITDA."
Kurt Workman, CEO and Co-founder
"Our strong revenue forecast and the improved vendor terms we previously outlined positioned us for positive gross margin trends before the implementation of the new tariffs, which have since affected our gross margin expectations. We continue to strive for full year 2025 adjusted EBITDA profitability."
Amanda Tweed Crawford, CFO
Strategic Positioning
1. Expanding Pediatric Health Platform via Owlet360 Subscription
Owlet360, launched officially in January 2025, has rapidly grown to over 48,000 paying subscribers, nearly doubling since the prior quarter. This subscription service delivers enhanced health insights and peace of mind, transforming Owlet from a hardware provider into a comprehensive pediatric health platform. The company is actively driving adoption through in-app messaging, email, SMS, and marketing campaigns, with plans to expand internationally later this year.
2. Healthcare Channel Penetration and Hospital Partnership
The landmark partnership with Children’s Hospital of the King’s Daughters enables infants to leave the hospital with Owlet’s BabySat and Dream Sock monitors, integrating data into clinical remote monitoring workflows. This consignment model and Medicaid reimbursement in 12 states via AdaptHealth set the stage for scaling in the healthcare market, a strategic growth vertical that diversifies revenue and enhances clinical validation.
3. Supply Chain Optimization and Tariff Mitigation
Owlet has proactively shifted manufacturing away from China to Vietnam and Thailand, reducing exposure to tariffs on Chinese imports. Although new 10% tariffs on Thailand and Vietnam imports pose a margin headwind, the company is exploring cost mitigation strategies. This supply chain agility positions Owlet to capitalize on tariff-driven market share gains as many competitors remain reliant on China manufacturing.
4. International Market Growth
International revenue doubled year-over-year, with Germany showing particularly strong sell-through growth. Owlet plans to leverage existing global sales channels and add new countries, further supported by the upcoming international rollout of Owlet360. This geographic diversification reduces reliance on the U.S. market and broadens growth avenues.
5. Brand Strength and Customer Loyalty
Owlet’s Dream Sock brand maintains a high net promoter score of 73 and low return rates, reflecting strong customer satisfaction. Baby registries, a leading adoption indicator, increased 63% year-over-year, underscoring sustained consumer demand and brand momentum in the nursery category.
Key Considerations
Owlet’s first quarter results underscore the company’s successful execution amid a dynamic macro environment, supported by clear strategic priorities.
- Subscription Upside: Owlet360’s rapid subscriber growth signals a promising recurring revenue stream that could materially shift the company’s revenue mix.
- Healthcare Channel Scalability: The hospital partnership and Medicaid reimbursement pave the way for broader clinical adoption, but scaling these channels will require time and continued regulatory engagement.
- Tariff Impact Management: While tariffs on Vietnam and Thailand imports introduce margin pressure, Owlet’s supply chain diversification and vendor negotiations mitigate risk and may provide competitive advantage.
- Seasonality and Revenue Cadence: Management expects sequential quarterly growth with a peak in Q4 due to holiday promotions, reflecting typical consumer buying patterns in infant products.
- Market Share Opportunity: Competitor exposure to China tariffs creates a favorable environment for Owlet to expand its infant monitor market share.
Risks
Owlet faces risks related to the evolving tariff landscape, potential shifts in consumer spending, and the complexity of scaling healthcare channel partnerships. Regulatory approvals and reimbursement policies remain critical variables. Additionally, macroeconomic uncertainty could impact consumer behavior despite current resilience.
Forward Outlook
For Q2 2025, Owlet expects continued sequential revenue growth, building on its strong Q1 base. Management projects full-year 2025 revenue in the range of $91 million to $95 million, representing 17% to 22% growth year-over-year. Gross margin guidance is set between 46% and 50%, reflecting tariff-related cost pressures. The company maintains its target for adjusted EBITDA profitability for the full year, balancing growth investments with operational discipline.
Takeaways
Owlet’s first quarter performance signals a successful pivot from consumer hardware toward a recurring revenue pediatric health platform, supported by strong product demand and strategic healthcare partnerships.
- Growth and Margin Expansion: The 43% revenue growth and 930 basis point gross margin improvement demonstrate effective execution and operational leverage.
- Platform Transformation: Owlet360 subscription adoption and healthcare channel breakthroughs are reshaping the business model toward higher-margin, recurring revenue streams.
- Future Focus: Investors should monitor subscription growth trajectory, healthcare channel scaling, and tariff developments as key drivers of Owlet’s medium-term financial trajectory.
Conclusion
Owlet’s Q1 2025 results confirm strong demand for its infant monitoring products and validate its strategic shift toward a broader pediatric health platform. Despite tariff headwinds, the company raised revenue guidance and remains focused on achieving full-year adjusted EBITDA profitability, positioning it well for durable growth and enhanced shareholder value.
Industry Read-Through
Owlet’s success in expanding subscription services and integrating infant health monitoring into clinical workflows reflects broader digital health trends emphasizing data-driven care and remote patient management. Its proactive supply chain adjustments highlight the importance of tariff risk mitigation in consumer medical device manufacturing. Other companies in pediatric monitoring and wearable health devices should watch Owlet’s healthcare channel partnerships as a model for reimbursement-driven growth and clinical validation. The tariff-driven competitive shifts underscore the need for geographic manufacturing diversification across the medical device sector.